Business Wire

Business Wire Shares Expert Knowledge on Communication 4.0 at Future Convention


Business Wire, the global leader in press release distribution, has once again organized a media event at the Future Convention, participating, together with partners such as Volkswagen AG, as the official sponsor and media partner. At the convention, over 500 visitors experienced digitalization, communications technology and innovation first-hand, including numerous forums and keynote speeches. Keeping in line with the future-oriented character of the Future Convention, and as part of its media event series, Business Wire launched a panel discussion on: “Public Relations in the Age of Communication 4.0, and on the topic of whether women might be better communicators.” With Christine Riedmann-Streitz (founder of MarkenFactory, marketing expert and author) as the moderator, specialists from renowned companies shared their know-how with the audience. You can follow the full-length podium discussion on Business Wire’s YouTube Channel.

This press release features multimedia. View the full release here:

Among those taking part in the discussion were Eva Pauli from fischer appelt relations GmbH, Corinna Laudert from Klenk & Hoursch AG, Anja Henningsmeyer from the Hessische Film- und Medienakademie, Marialejandra Rodriguez from KALEIDOSCOPE Innovation Consulting and, last but not least, Yannis Salavopoulos from CAPITALS Circle Group GmbH & Global Sustain GmbH.

As part of the lively exchange on future ideas and trends, Business Wire also presented a “Business Wire Expert Talks” video for PR, marketing and communications experts. In the video, the experts from the podium discussion provide valuable insights and impart their knowledge on leading topics in the communications industry. Key points include diversity in PR, visibility in the digital overflow, digital branding, the challenges facing digital communication, Love Brands and the competitiveness of major companies. “Business Wire Expert Talks” is now available to the public on YouTube.

The Future Convention brings together up-and-coming talents, business leaders and potential investors with the aim of turning the spotlight on innovation and passing on knowledge for optimizing existing business models. It also seeks to promote university graduates and start-ups, to discuss the business and socio-political challenges of digitalization and to develop collaborative solutions.

You can view press images of the event here.

Patron: Brigitte Zypries, Federal Minister for Economic Affairs and Energy
Sponsor: LPR Hessen
Academic partner: Hochschule der Wirtschaft für Management, Mannheim
Partner: BKK·VBU, Business Wire, IHK Offenbach am Main, Spectos GmbH, Standort Plus der Wirtschaftsförderung Kreis Offenbach, Volkswagen AG

About Business Wire:

Business Wire, a company from the Warren Buffett group, Berkshire Hathaway Inc., is the global leader in the distribution of corporate press releasesregulatory disclosures and multimedia content. Experts from the investor relations, public relations, public policy and marketing sectors rely on Business Wire to accurately distribute market-moving news and multimedia content. The company also hosts online newsrooms and IR websites, builds content marketing platforms, generates social engagements and provides audience analysis that improves interaction with specific target markets. Founded in 1961, Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented simultaneous NX Network. Business Wire has 29 offices and 20 full-service newsrooms worldwide to securely meet the varying needs of communications professionals and news consumers.

You can find further information on and on Tempo, the source for the latest trends in the communications sector; follow updates on Twitter: @BusinessWireDE and @BusinessWire or on Facebook.

Click here to receive mobile alerts from Business Wire.

About the Future Convention and the Future Network

With the Future Network as well as the Future Award and Future Convention initiatives, and as a communication users’ association, the DVPT (German Association of Post Offices, Information Technology and Telecommunications) fosters integral, interdisciplinary thinking with the aim of meeting, at an early stage and using forward-looking concepts, the demands that our digitalized society is constantly creating.

Contact information

Business Wire
Seval Dogan
Tel.: +49 69 91 50 66 0

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi